Category: Zacks Small Cap Research
By Ian Gilson, PhD, CFA NASDAQ:SNES READ THE FULL SNES RESEARCH REPORT SenesTech (NASDAQ:SNES) has announced that it will raise $1.42 million gross (about $1.28 net) from the sale of 3.55 million shares at $0.40 and the issuance of 3.55 million warra ...
By Brian Marckx, CFANASDAQ:MTBC READ THE FULL MTBC RESEARCH REPORT MTBC Inc (NASDAQ:MTBC) started 2020 with a bang, announcing and closing on their largest acquisition to-date less than two weeks into the new year. CareCloud Corporation brings a prop ...
By Zacks Small-Cap ResearchOTC:JMDA READ THE FULL JMDA RESEARCH REPORT ‣ Jerrick (OTC:JMDA) is a five-year-old company, which spent the startup phase developing a revenue-generating platform, built primarily for the creator and the broader creative c ...
By John Vandermosten, CFANASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics (NASDAQ:TENX) updated investors on its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial status last week in a January 13, 2020 rel ...
By David Bautz, PhDNASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Underway On January 10, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of St ...
By Ian Gilson, PhD, CFANASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Stargus, one of Marrone Bios (NASDAQ:MBII) fungicides, has been approved for immediate use in California for use on several crops, including grapes, vegetables and strawberries. St ...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAF READ THE FULL MDNA.TO RESEARCH REPORT Business Update Highly Encouraging Results for MDNA55 When Comparing with Synthetic Control Arm On January 13, 2020, Medicenna Therapeutics Corp. (TSX:MDNA.TO) (OTC:MDN ...
NASDAQ:SNES To accelerate growth in the domestic market, SenesTech (NASDAQ:SNES) has launched an online store (https://store.senestech.com) since mid-December 2019. While ContraPest is also available through national and regional distributors, the on ...
By David Bautz, PhDNASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update BXCL501 Update BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a clinical stage biopharmaceutical company focused on two lead development programs: BXCL501 – a sublingual f ...
By David Bautz, PhDOTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT Business Update Preparing for OxC-beta™ Approval in China On December 17, 2019, Avivagen, Inc. (OTC:VIVXF) announced it has entered into an agreement with COFCO Biotechnology Co. Ltd. i ...